Growth hor­mone from No­vo Nordisk is in short­age over man­u­fac­tur­ing de­lays

No­vo Nordisk’s growth hor­mone Norditropin is in short­age be­cause of man­u­fac­tur­ing de­lays, ac­cord­ing to an FDA site that tracks drug short­ages as well as the Amer­i­can So­ci­ety of Health-Sys­tem Phar­ma­cists’ short­ages list.

The FDA has short­ages of the drug list­ed for its 5, 10, 15 and 30 mg dos­es, while the phar­ma­cists’ group, al­so known as ASHP, re­port­ed short­ages of the same dos­es, ex­cept for the 15 mg ver­sion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN